Physician profile
Patrick L Fraley
NPI 1376623165
$5,079.76
in general payments reported to CMS, 2019-2025
15 companies · $867 in 2025
The $867 reported for 2025 was more than what 76% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $336 · 2021: $533 · 2022: $597 · 2023: $656 · 2024: $968 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,491.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,346.59 | 2019-2025 | Inspire |
| Stryker Corporation | $423.19 | 2019-2025 | Scopis Ent |
| Intersect Ent, INC. | $311.72 | 2019-2020 | |
| Aerin Medical INC. | $205.47 | 2020-2025 | |
| Optinose US, INC. | $182.72 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $137.11 | 2021-2025 | Dupixent |
| Kls-Martin L.P. | $106.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $77.35 | 2022-2025 | Tezspire |
| Itamar Medical INC | $67.23 | 2021-2024 | Watchpatone |
| Depuy Synthes Sales INC. | $58.57 | 2024 | Matrixmandible, Matrixwave, Matrixmidface |
| Pfizer INC. | $51.12 | 2024 | |
| Glaxosmithkline, LLC. | $38.54 | 2024 | Nucala |
| Neurent Medical Limited | $32.71 | 2024 | Neuromark Device, Neuromark Radiofrequency Console |
| Acclarent, INC | $25.82 | 2019 | |
| Ambu INC. | $15.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Fraley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.